Barclays Lowers ICON Public (NASDAQ:ICLR) Price Target to $275.00

ICON Public (NASDAQ:ICLR) had its price objective decreased by Barclays from $330.00 to $275.00 in a research note released on Friday morning, Benzinga reports. Barclays currently has an overweight rating on the medical research company’s stock.

Other equities research analysts have also recently issued research reports about the company. The Goldman Sachs Group decreased their price objective on ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a report on Friday. StockNews.com cut ICON Public from a “buy” rating to a “hold” rating in a report on Thursday, September 19th. Robert W. Baird cut ICON Public from an “outperform” rating to a “neutral” rating and set a $340.00 price objective on the stock. in a report on Thursday, October 24th. Redburn Atlantic initiated coverage on ICON Public in a report on Monday, October 14th. They set a “neutral” rating and a $311.00 price objective on the stock. Finally, JPMorgan Chase & Co. decreased their price objective on ICON Public from $375.00 to $280.00 and set an “overweight” rating on the stock in a report on Friday. Four research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $304.27.

ICON Public Stock Up 4.5 %

ICLR opened at $230.50 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.31 and a quick ratio of 1.31. The business has a 50 day simple moving average of $295.86 and a 200-day simple moving average of $309.61. The stock has a market capitalization of $19.02 billion, a P/E ratio of 26.86, a P/E/G ratio of 1.35 and a beta of 1.22. ICON Public has a 12 month low of $220.01 and a 12 month high of $347.72.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing the consensus estimate of $3.72 by ($0.37). The firm had revenue of $2.03 billion during the quarter, compared to analysts’ expectations of $2.13 billion. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The business’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same period in the previous year, the business earned $3.10 earnings per share. On average, equities analysts anticipate that ICON Public will post 14.53 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ICON Public

Hedge funds have recently bought and sold shares of the company. Liontrust Investment Partners LLP boosted its position in shares of ICON Public by 19.5% during the 2nd quarter. Liontrust Investment Partners LLP now owns 119,728 shares of the medical research company’s stock valued at $37,531,000 after acquiring an additional 19,546 shares in the last quarter. Kornitzer Capital Management Inc. KS boosted its position in shares of ICON Public by 15.9% during the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 95,753 shares of the medical research company’s stock valued at $30,016,000 after acquiring an additional 13,163 shares in the last quarter. Whittier Trust Co. boosted its position in shares of ICON Public by 12.3% during the 3rd quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company’s stock valued at $1,155,000 after acquiring an additional 441 shares in the last quarter. Sara Bay Financial acquired a new stake in shares of ICON Public during the 3rd quarter valued at about $1,143,000. Finally, Motco boosted its position in shares of ICON Public by 1.5% during the 1st quarter. Motco now owns 3,882 shares of the medical research company’s stock valued at $1,304,000 after acquiring an additional 59 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.